Susquehanna Fundamental Investments’s Corvus Pharmaceuticals CRVS Stock Holding History

Susquehanna Fundamental Investments’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-13,790	Closed	-$11K	–	1253
2022 Q3	$11K	Buy	+13,790	New	+$13.2K	﹤0.01%	1416
2022 Q1	$23K	Buy	+13,790	New	+$25.2K	﹤0.01%	1510
2021 Q1	–	Sell	-42,452	Closed	-$151K	–	1544
2020 Q4	$151K	Sell	42,452 -11,676	-22%	-$47K	﹤0.01%	1393
2020 Q3	$217K	Buy	+54,128	New	+$216K	0.01%	1171

Other funds holding CRVS

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Susquehanna Fundamental Investments's CRVS Position: Q4 2022 in Review

Susquehanna Fundamental Investments sold out of Corvus Pharmaceuticals (CRVS) in Q4 2022, closing a stake of 13,790 shares — an estimated $11K sold.

Susquehanna Fundamental Investments first reported a position in CRVS in Q3 2020 and held it in 4 quarters. The position peaked at $217K in Q3 2020. 42 funds tracked by Wall St. Rank hold CRVS as of Q4 2022.

Susquehanna Fundamental Investments reported no remaining Corvus Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Susquehanna Fundamental Investments sold 13,790 Corvus Pharmaceuticals shares in Q4 2022, an estimated $11K.
Susquehanna Fundamental Investments first reported a position in Corvus Pharmaceuticals in Q3 2020 and held it in 4 quarters.
Susquehanna Fundamental Investments's Corvus Pharmaceuticals position peaked at $217K in Q3 2020.
42 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q4 2022.

Based on Susquehanna Fundamental Investments's 13F filing for Q4 2022, filed 14 Feb 2023.